2022-12-01 14:40
Biovica, active in cancer diagnostics, today announces that the company has employed a sales team of total of eight people to secure a fast and smooth launch and the further commercial development of DiviTum® TKa on the US market. Biovica’s...
2022-11-22 14:55
Biovica, active in cancer monitoring, today announces that the unique study design of the TK IMPACT trial, using the DiviTum® TKa blood test, will be presented as a poster at the world’s largest breast cancer symposium, SABCS, on December 8...
2022-11-22 14:50
Biovica, active in cancer monitoring, today announces that results from a study using the DiviTum® TKa blood test will be presented at the world’s largest breast cancer symposium, SABCS, on December 8. The results support using DiviTum®...
2021-04-23 08:30
Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at...
2021-01-18 08:00
DiviTum®TKa has been selected to be included in the new prospective clinical study TIRESIAS, with the aim of investigating if DiviTum®TKa can be used to identify early resistance to treatment by a CDK4/6 inhibitor in combination with an aromatase...
2021-01-12 11:50
Biovica's CEO and main shareholder Anders Rylander has, to facilitate the administration of the company's warrant program 3, lent 127,000 shares to Pareto Securities AB. The program comprises 200,000 options, of which 145,000 options have been...
2020-11-23 08:00
DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring...
2020-11-20 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from the European multicenter study PYTHIA will be presented at the world´s leading breast cancer conference, SABCS, in early December. The PYTHIA study...
2020-11-19 08:00
Biovica, active in cancer diagnostics, today announced that positive DiviTum®TKa results from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, will be presented at the world´s leading...
2020-11-18 08:00
November 18, 2020 -- Biovica, active in cancer diagnostics, today announced that initial results from the PROMISE study (NCT03281902) will be presented at the San Antonio Breast Cancer Symposium (December 8-11, 2020). The PROMISE Study is evaluating the...
>4,500
Numbers of patients in studies
28
Publications
19
Pharma Projects